This episode covers a qualitative study on how fragmented care systems fail women experiencing suicidality during menopause, a promising new blood marker for detecting bone thinning early, and the launch of one of the most detailed long-term menopause studies ever designed. Friday format — research grounded, lighter in places, and worth your weekend thinking.

Key Takeaways:

• A 2026 qualitative study found that clinicians and caregivers consistently identified fragmented, siloed care as a key failure point when menopausal women reached a mental health crisis — menopause and mental health services often don't talk to each other.

• Suicidality during perimenopause and menopause is real and documented, but it remains dramatically undertreated and under-recognized in primary care.

• Xylosyltransferase-I (XT-I) is a blood enzyme that may signal bone thinning earlier than current standard tests — still early-stage research, but worth watching.

• The KiSO-DP cohort study will track women through the full menopausal transition using biological, psychological, and lifestyle data collected from the same participants over time — the kind of within-person design that produces much more reliable answers than snapshot studies.

• Research on menopause is getting more ambitious and more rigorous — and the questions being asked are finally catching up to what women have been reporting for decades.

Sources & References:

• Menopausal suicidality and fragmented care: carer and clinician perspectives (https://pubmed.ncbi.nlm.nih.gov/42625547/) - PubMed

• Xylosyltransferase-I as a biomarker for postmenopausal osteoporosis (https://pubmed.ncbi.nlm.nih.gov/42624941/) - PubMed

• KiSO-DP: Women in healthy transition deep phenotyping cohort study protocol (https://pubmed.ncbi.nlm.nih.gov/42624590/) - PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-21-listener-story

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode covers three things getting attention right now: new data showing menopause symptoms cost workers nearly 35 workdays a year, a 2026 study linking menopausal insomnia directly to dementia risk, and a NAMS journal paper raising the intersection of intimate partner violence and menopause care — a conversation that's been missing from the field for too long.

Key Takeaways:

• New research estimates that perimenopause and menopause symptoms cost employees nearly 35 workdays per year in lost productivity — not just absences, but impaired performance while present.

• A 2026 PubMed study frames menopausal insomnia as a point in the chain leading to dementia risk — and, critically, as something that can be addressed, which means sleep isn't just about feeling rested.

• Poor sleep during menopause disrupts the brain's overnight cleanup process, which is directly tied to the kind of protein buildup associated with Alzheimer's disease.

• A paper in the NAMS journal identifies intimate partner violence as an underexplored factor in menopause care — abuse affects stress hormones, sleep, and access to healthcare in ways that can make symptoms significantly worse.

• Women in abusive situations may have their menopause symptoms dismissed, undertreated, or go entirely unaddressed — and clinicians currently have almost no training to recognize the overlap.

Sources & References:

• Perimenopause and menopause symptoms may cost employees nearly 35 workdays a year (https://news.google.com/rss/articles/CBMitAFBVV95cUxNY0RIMzI2ZmlSdXhsV2k4LW5oeFoxTmhOaFEyeU1TdDR5NXVXUU5zQWNWOEJaMC1abVFGQkM4U1hXb0tuNUwxbFFXM2V3MndIMW5GRTBreC05ck5RUENLa2g0SmpsSjNlZFVCQ3g0RU5RZzhZRUs5QmRIRDdVLWgxUzdoamRFZ1FTWkJYMG5aSU12OTJwNUpBNlJVeV9iQkZGN2NtMlhUc0NnbEo2aEUzSWJWMzQ?oc=5) - Fast Company

• Menopausal insomnia as a modifiable node of dementia risk: Mechanistic insights and intervention strategies (https://pubmed.ncbi.nlm.nih.gov/42619312/) - PubMed

• The overlooked intersection of intimate partner violence and menopause care (https://pubmed.ncbi.nlm.nih.gov/42610458/) - Menopause (NAMS Journal)

Listen with full show notes: https://hotflasher.com/episodes/2026-08-20-influencer-roundup

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

JAMA takes a hard look at the exploding menopause care market and asks which treatments actually have evidence behind them. A new NAMS study finds that type 2 diabetes significantly worsens menopause symptoms — more than most people realize. And a peer-reviewed paper asks why clinicians almost never screen for intimate partner violence during menopause care visits.

Key Takeaways:

• The menopause care market is growing fast, but JAMA's review finds the evidence for many emerging treatments hasn't kept pace with the marketing.

• Hormone therapy and a small number of non-hormonal options have the strongest research backing; most supplements and "menopause kits" do not.

• A Korean study of midlife women found that those with type 2 diabetes reported significantly more menopause symptoms — and more severe ones — than women without diabetes.

• Postmenopausal women with type 2 diabetes had a higher overall symptom burden, suggesting blood sugar management may directly affect quality of life during menopause.

• Research published in the NAMS journal finds that clinicians rarely screen for intimate partner violence during menopause care visits, despite evidence that IPV affects both access to care and symptom severity.

Sources & References:

• The overlooked intersection of intimate partner violence and menopause care (https://pubmed.ncbi.nlm.nih.gov/42610458/) - Menopause (NAMS Journal)

• Association between type 2 diabetes and menopausal symptoms in Korean midlife women (https://pubmed.ncbi.nlm.nih.gov/42549660/) - Menopause (NAMS Journal)

Listen with full show notes: https://hotflasher.com/episodes/2026-08-19-myth-busting

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode digs into why some women have significantly worse menopause symptoms than others, looks at the surprisingly plausible case for antihistamines as a symptom tool, and breaks down what a new SWAN study says about midlife inflammation and your future memory.

Key Takeaways:

• A newly identified biological difference — in how certain women's nervous systems respond to dropping estrogen — may explain why symptom severity varies so much from person to person.

• Antihistamines target histamine, a chemical that interacts with the same brain pathways involved in hot flashes and mood swings; the evidence is early but the mechanism is real.

• A study from the long-running SWAN research project found that women with higher levels of a specific inflammation marker (GlycA) in midlife had lower working memory scores years later.

• Not all inflammation signals worked the same way — two immune proteins (complement C3 and C4) were actually associated with better cognitive outcomes when they increased, which complicates the "all inflammation is bad" narrative.

• The SWAN finding points to midlife — not just post-menopause — as a window that may matter for long-term brain health.

Sources & References:

• Scientists discovered one reason menopause symptoms might be worse for certain women (https://news.google.com/rss/articles/CBMiiAFBVV95cUxNRXJld3p2V09adzdLdk83cUNMMlFnbnlodngxeERaZUJrVFdMV1BFa191TEN4WVZnMjcxc1VYYkJ0YlFhNXVocmFtUDJDby13Sl9Pa0tCQkxJUnoyek03Tlk5RDRSWG50Qks1Y0N2NmlDeHJkeGdrV1ViM2pDcFFZdHhKWXVVTE9q?oc=5) - Women's Health

• Can antihistamines really help with PMDD and menopausal symptoms? (https://news.google.com/rss/articles/CBMihAFBVV95cUxNa0Y1bzRYMlZDUlJlamVjZTJjWEZSd1QzMTFVbDBwR1ZPcDcxRGF4ODNxd0lSNUtiQ0dGZXRsNTAzOGFqWVJ6VTVfOGVOU2VZZzRwY2NwVkFZRnRwU1p6Y2RXWUtnTlVRLTZ6eWFwOVV6RzJxUERpSFhzQUZ1cTVXdXEtQlQ?oc=5) - The Guardian

• Inflammatory and immune biomarkers over midlife and future cognition in women: the SWAN HDL Ancillary Study (https://pubmed.ncbi.nlm.nih.gov/42549661/) - NAMS Journal / PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-18-symptom-spotlight

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode covers three research and news stories: a new study suggesting hormone therapy may reduce Alzheimer's risk by around 35%, a major meta-analysis confirming that strength training does protect bone density after menopause (with some important caveats on how big that effect actually is), and a data privacy investigation finding that menopause apps have been selling users' intimate health information — and in many cases, still are.

Key Takeaways:

• A new study found that women who used hormone therapy had roughly 35% lower Alzheimer's risk — but this is observational research, not a clinical trial, and the result does not mean HRT prevents Alzheimer's.

• A systematic review of multiple studies found that high-intensity and strength training does increase bone density in postmenopausal women, though the effect sizes were described as small — real, but not dramatic.

• The type of exercise matters: impact training (like jumping) and strength training both showed benefits for bone density, and the research supports combining them rather than choosing one.

• Multiple menopause apps have sold users' intimate health data — including symptom logs, cycle history, and other private details — often without clear disclosure, and the practice is reportedly ongoing.

• If you use a menopause or period tracking app, it is worth checking its privacy policy specifically for language about data sharing with third parties or "partners."

Sources & References:

• Alzheimer's risk may be 35% lower with common menopause treatment, study finds (https://news.google.com/rss/articles/CBMipAFBVV95cUxPR2M3NVFTQktWaW5Pc3dMcWNwZnNfUnhtaGRnZlpwSHIzUjNUU1JmaTZ5aFdsWnl1WXRaQ2R1YlYyMm5wWmVkdGc3bHkxSjI5ekpHdVUzMExoX1hDRllScHcwX3ZBSnJUVVItNFZzeFZRcUZTUGtjbElZc0dpTkU1ekdzLXhXcHNBcUd5VExRUEVWSzZ6ZUM3dWFPYVNYVlpNUmY4RdIBqgFBVV95cUxQQm5Gd3F0S01iejNscTdTcDNEZEhQeGNadGJNV1VMRnVwMG1peUVOakkzeDRZZDFrNVdXaXF5YkUwb1R1elUyanVkNHMtRVFjdDVtRlNtMDJsdU5iWVBNM3QzWHdfYl9SaHBCLWxnZWM4cHBmNzk2b09jSzBBZnNDMldjQ3hBVUl2bENHOUd6RjdpWFpkLXFnLUpWd3Z0M1NFUXNRN0Y0Tk5oZw) - Fox News

• Systematic review and meta-analysis: high-intensity, impact, and strength training effects on bone density in pre- and postmenopausal women (https://pubmed.ncbi.nlm.nih.gov/42578477/) - Menopause (NAMS Journal) via PubMed

• Millions of women's intimate health data has been sold by menopause apps — and it's still happening (https://news.google.com/rss/articles/CBMilAFBVV95cUxNTWlUVjlzbkdfVVQ2MTUxa29PWXo4WVk1RG9TRjk3UFpYbkVhb1JXbEpGeFA3bkdPWGpGeWRqaF9lTVFRdG9sbUtXUERKamdHdWZLUTNZRFRGZFJDOG1sY1VYTjRTRTBDNTVXaGRiU3FXQUlHS0tuQldYdDJtV2xHSEZxODdwUjRoa1lFRnVuektnZ1Q2) - The Independent

Listen with full show notes: https://hotflasher.com/episodes/2026-08-17-research-roundup

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode covers two new approaches to catching osteoporosis earlier in postmenopausal women — one using AI analysis of routine chest X-rays, one using a clinical prediction tool called a nomogram — plus a look at a newly defined syndrome called PMOS that links ovarian, metabolic, and cardiovascular risk in ways medicine is only beginning to map. All three studies published in August 2026.

Key Takeaways:

• A new AI tool can analyze routine chest X-rays to flag women who may need osteoporosis evaluation earlier — no additional scan required.

• A separately published nomogram offers a scoring model to help predict postmenopausal osteoporosis risk using clinical variables.

• Postmenopausal women with polycystic ovary syndrome (PCOS) history may carry elevated cardiometabolic risk under a newly proposed framework called PMOS.

• Most women don't get a baseline DEXA scan until age 65 — both the AI screening tool and the nomogram are attempts to close that gap.

• The PMOS research signals that PCOS doesn't simply disappear after menopause; its metabolic fingerprint may persist and compound cardiovascular risk.

Sources & References:

• Construction and validation of a nomogram for diagnosing postmenopausal osteoporosis (https://pubmed.ncbi.nlm.nih.gov/42596822/) - PubMed

• AI-derived opportunistic screening using chest radiographs to identify bone mineral density patterns (https://pubmed.ncbi.nlm.nih.gov/42595903/) - PubMed

• Cardiometabolic risk in postmenopausal women with polyendocrine metabolic ovarian syndrome (PMOS) (https://pubmed.ncbi.nlm.nih.gov/42595557/) - PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-14-listener-story

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode covers three studies published in August 2026 touching on fibroid care in the perimenopausal transition, fatty liver disease risk accumulation in postmenopausal women, and what standard DXA bone scans may not be capturing about bone metabolism. Nykki examines what the research actually says, where the gaps are, and why these conditions intersect with menopause more than most clinicians discuss.

Key Takeaways:

• Uterine fibroids (leiomyomas) affect up to 70-80% of women by age 50, but treatment decisions are still largely one-size-fits-all rather than tailored to symptom phenotype, reproductive stage, or long-term goals.

• A 2026 study found that in postmenopausal women, it's not just body fat but the accumulation of multiple cardiometabolic risk factors together — insulin resistance, dyslipidemia, hypertension — that predicts more severe hepatic steatosis (fatty liver).

• Standard DXA scans measure bone density but don't capture bone turnover rate — how fast bone is being broken down and rebuilt — which matters especially during and after menopause when that rate accelerates.

• Bone turnover markers (blood and urine tests) can give a more dynamic picture of skeletal health than a single DXA reading, and research suggests they may be underused in routine postmenopausal care.

• Women with multiple cardiometabolic risk factors after menopause may warrant liver screening conversations with their doctors, even in the absence of symptoms.

Sources & References:

• From prevalence to precision: Integrating phenotype, symptoms, reproductive goals, and treatment in leiomyoma care (https://pubmed.ncbi.nlm.nih.gov/42590871/) - PubMed

• Adiposity and cumulative cardiometabolic risk factors as determinants of hepatic steatosis severity in postmenopausal women (https://pubmed.ncbi.nlm.nih.gov/42590200/) - PubMed

• Bone turnover markers, DXA and mineral metabolism in long-term kidney transplant recipients: a cross-sectional comparative study (https://pubmed.ncbi.nlm.nih.gov/42590077/) - PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-13-influencer-roundup

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

Today's episode looks at a new flaxseed and Linusorb study claiming to ease menopausal symptoms through non-hormonal estrogen receptor activation, a rare breast cancer case report with a warning relevant to anyone in or around menopause, and new quality-improvement research on why menopause conversations in primary care are still falling short — and what's actually being done about it.

Key Takeaways:

• A new study found flaxseed and Linusorb may reduce menopausal symptoms and bone loss by activating estrogen receptors non-hormonally, but the evidence base is early and the leap from mechanism to clinical recommendation is a long one.

• Metastatic breast cancer can spread to the cervix and endometrium and look exactly like a primary gynecologic cancer — a case report published today is a reminder that unusual gynecologic symptoms always warrant thorough workup, not assumptions.

• A 2026 quality improvement project found that structured tools and checklists in primary care significantly increased the rate of menopause conversations — but the fact that we need a QI project to get doctors talking about menopause tells its own story.

• Research on phytoestrogens remains genuinely mixed; the women most likely to benefit from dietary interventions appear to be those who produce equol, a compound not everyone's gut microbiome can make from lignans.

• The average primary care appointment is not designed for menopause — it's a condition that spans sleep, mood, bone health, cardiovascular risk, and more, and five minutes doesn't get you there.

Sources & References:

• Flaxseed and Linusorb synergistically ameliorate menopausal symptoms through non-hormonal activation of estrogen receptors (https://pubmed.ncbi.nlm.nih.gov/42581697/) - PubMed

• Metastatic breast cancer to the cervix and endometrium mimicking a primary gynecologic malignancy (https://pubmed.ncbi.nlm.nih.gov/42581665/) - PubMed

• Facilitating menopause discussions in primary care: a quality improvement project (https://pubmed.ncbi.nlm.nih.gov/42580869/) - PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-12-myth-busting

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode looks at three new papers: one connecting diet, insulin resistance, and a specific kind of lung impairment in postmenopausal women; one calling out psychiatric treatment guidelines for failing midlife women during menopause; and one mouse study on a traditional Chinese herbal formula and its effects on brain inflammation. Nykki reads the methods, names what the evidence actually supports, and is direct about where each study falls short or raises something worth watching.

Key Takeaways:

• A 2026 cross-sectional study found that lower dietary quality in postmenopausal women was associated with a specific lung function pattern called PRISm — and insulin resistance appears to be part of the mechanism connecting diet to lung impairment.

• Cross-sectional studies cannot establish cause and effect — they show association, not direction — so this finding is hypothesis-generating, not actionable on its own.

• Australia and New Zealand's psychiatric guidelines for schizophrenia largely ignore how menopause affects antipsychotic medication needs, leaving midlife women undertreated or incorrectly dosed at a critical biological transition.

• A 2026 mouse study found that the Chinese herbal formula Chaihu Shugan San reduced neuroinflammation and improved markers of hippocampal function — but mice are not humans, and the pathway from animal model to clinical use is long and frequently fails.

• The schizophrenia guideline gap reflects a systemic problem in medicine: women's health is often studied as a deviation from a male default, and life-stage changes like perimenopause are treated as edge cases rather than core clinical variables.

Sources & References:

• Dietary quality, insulin resistance, and lung function in postmenopausal women (https://pubmed.ncbi.nlm.nih.gov/42577152/) - PubMed

• RANZCP schizophrenia guidelines and the unmet needs of midlife women (https://pubmed.ncbi.nlm.nih.gov/42576669/) - PubMed

• Chaihu Shugan San, microglial polarization, and hippocampal plasticity in menopausal mice (https://pubmed.ncbi.nlm.nih.gov/42576491/) - PubMed

Listen with full show notes: https://hotflasher.com/episodes/2026-08-11-symptom-spotlight

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.

This episode covers three new papers from the NAMS journal: a SWAN ancillary study connecting midlife inflammatory biomarkers to future working memory, a randomized controlled trial on a probiotic formula for menopausal symptoms, and a narrative review exposing what medical schools are — and mostly aren't — teaching about menopause. Research credibility and medical-system frustration lenses throughout.

Key Takeaways:

• Higher baseline GlycA (an inflammatory glycoprotein marker) was associated with lower future working memory in the SWAN HDL Ancillary Study — suggesting midlife inflammation may be a modifiable risk factor for cognitive decline.

• Complement proteins C3 and C4 showed a more complex picture: higher baseline complement factor 4 and increases in both C3 and C4 over time appeared cognitively protective, complicating a simple "less inflammation = better brain" narrative.

• A randomized controlled trial found a probiotic formula was associated with improvements in menopausal symptoms and quality of life — a real RCT result, not a supplement ad, though the researchers acknowledge more work is needed to confirm mechanism.

• A narrative review of undergraduate medical curricula found that menopause education remains inconsistent, under-resourced, and frequently absent — meaning the knowledge gap starts well before residency.

• The doctor who doesn't know how to counsel you on menopause very likely wasn't taught how. That's a systemic failure, not an individual one — and it has downstream consequences for every woman who hits perimenopause and gets a blank stare from her GP.

Sources & References:

• Inflammatory and immune biomarkers over midlife and future cognition in women: the SWAN HDL Ancillary Study (https://pubmed.ncbi.nlm.nih.gov/42549661/) - PubMed / Menopause (NAMS Journal)

• Efficacy of a probiotic formula in the management of menopausal symptoms and quality of life: a randomized controlled trial (https://pubmed.ncbi.nlm.nih.gov/42549656/) - PubMed / Menopause (NAMS Journal)

• Menopause education in undergraduate medical curricula: a narrative review of teaching models, content gaps, and learner preparedness (https://pubmed.ncbi.nlm.nih.gov/42517363/) - PubMed / Menopause (NAMS Journal)

Listen with full show notes: https://hotflasher.com/episodes/2026-08-10-research-roundup

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.